Compare · ABBV vs PGEN
ABBV vs PGEN
Side-by-side comparison of AbbVie Inc. (ABBV) and Precigen Inc. (PGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PGEN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $469.68B, about 180.2x PGEN ($2.61B).
- Over the past year, ABBV is up 27.5% and PGEN is up 71.5% - PGEN leads by 44.0 points.
- ABBV has been more active in the news (17 items in the past 4 weeks vs 12 for PGEN).
- ABBV has more recent analyst coverage (25 ratings vs 4 for PGEN).
- Company
- AbbVie Inc.
- Precigen Inc.
- Price
- $265.73+0.42%
- $7.28+1.61%
- Market cap
- $469.68B
- $2.61B
- 1M return
- +3.46%
- +34.32%
- 1Y return
- +27.54%
- +71.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 17
- 12
- Recent ratings
- 25
- 4
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Precigen Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Latest ABBV
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
- SEC Form 424B5 filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest PGEN
- Director Agee Nancy H bought $24,662 worth of shares (3,411 units at $7.23), increasing direct ownership by 1% to 309,187 units (SEC Form 4)
- Chief Legal Officer Lehr Donald P. converted options into 5,208 shares and covered exercise/tax liability with 2,488 shares, increasing direct ownership by 0.36% to 758,181 units (SEC Form 4) (tax liability)
- Chief Financial Officer Thomasian Harry Jr. converted options into 7,291 shares and covered exercise/tax liability with 3,577 shares, increasing direct ownership by 1% to 258,249 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Shah Rutul R exercised 57,500 shares at a strike of $2.03, sold $375,000 worth of shares (50,000 units at $7.50) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,647 shares, increasing direct ownership by 0.83% to 468,865 units (SEC Form 4) (withholding tax)
- Chief Commercial Officer Tennant Phil exercised 84,374 shares at a strike of $1.51, covered exercise/tax liability with 2,585 shares and sold $593,745 worth of shares (79,166 units at $7.50) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 141,992 units (SEC Form 4) to satisfy withholding tax
- President and CEO Sabzevari Helen converted options into 20,833 shares and covered exercise/tax liability with 10,184 shares, increasing direct ownership by 0.28% to 3,779,521 units (SEC Form 4) to satisfy withholding obligation
- Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
- Chief Operating Officer Shah Rutul R sold $224,590 worth of shares (32,739 units at $6.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 465,012 units (SEC Form 4)
- SEC Form 10-Q filed by Precigen Inc.
- Precigen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits